Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=3596
A key issue affecting the market is the recall of Medtronic plc’s Implantable Cardioverter Defibrillators (ICDs) Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) in July 2023. The recall was due to concerns about the devices’ ability to deliver sufficient energy during high voltage therapy, which could result in severe consequences like cardiac arrest.
The defibrillator market is segmented into product types, age groups, end users, and geographic regions. Product types include Implantable Cardioverter Defibrillators (ICDs) such as Transvenous ICDs (Cardiac Resynchronization Therapy Defibrillators, Dual-Chamber ICDs, Single-Chamber ICDs) and Subcutaneous ICDs, as well as External Cardiac Defibrillators (Manual ECD, Automated ECD [Semi-automated, Fully-automated], Wearable ECD).
The Implantable Cardioverter Defibrillators segment is expected to dominate the market in 2024, driven by increased adoption for preventing sudden cardiac arrest. Technological innovations like the CellAED by Rapid Response Revival Research Ltd, launched in March 2022, further support this segment. The CellAED is a user-friendly, portable device designed to improve survival rates during sudden cardiac arrest.
By age group, adults are projected to hold the largest market share in 2024. The higher prevalence of cardiovascular risk factors such as obesity and sedentary lifestyles in adults compared to children contributes to this trend. Data from the Sudden Cardiac Arrest Foundation shows a significantly higher annual incidence of out-of-hospital cardiac arrests in adults, driving demand for defibrillators.
Among end users, hospitals are expected to account for the largest market share in 2024. Hospitals provide extensive healthcare services and infrastructure, making them the primary setting for cardiovascular care and defibrillator use.
Browse in depth https://www.meticulousresearch.com/product/defibrillator-market-3596
One significant issue is the recall of Medtronic plc’s Implantable Cardioverter Defibrillators (ICDs) Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) in July 2023. The recall was due to concerns over the devices’ ability to deliver adequate energy during high voltage therapy, potentially leading to severe outcomes such as cardiac arrest.
A notable issue is the recall of Medtronic plc’s Implantable Cardioverter Defibrillators (ICDs) Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) in July 2023. The recall was due to concerns about the devices’ performance in delivering adequate energy during high voltage therapy, potentially leading to serious outcomes like cardiac arrest.
The report segments the defibrillator market by product type, age group, end user, and geography. Product categories include Implantable Cardioverter Defibrillators (ICDs) such as Transvenous ICDs (Cardiac Resynchronization Therapy Defibrillators, Dual-Chamber ICDs, Single-Chamber ICDs) and Subcutaneous ICDs, as well as External Cardiac Defibrillators (Manual ECD, Automated ECD [Semi-automated, Fully-automated], Wearable ECD).
Among these, the Implantable Cardioverter Defibrillators segment is expected to dominate the market in 2024. This is due to the growing adoption of these devices for preventing sudden cardiac arrest. Innovations such as the CellAED by Rapid Response Revival Research Ltd, introduced in March 2022, support this segment’s growth. The CellAED is a portable, user-friendly device designed to improve survival rates during sudden cardiac arrest.
By age group, adults are projected to represent the largest market share in 2024. The higher prevalence of cardiovascular risk factors such as obesity and sedentary lifestyles in adults compared to children contributes to this trend. Data from the Sudden Cardiac Arrest Foundation indicates a significantly higher annual incidence of out-of-hospital cardiac arrests in adults.
Geographically, North America is forecasted to lead the market in 2024, supported by high cardiovascular disease rates, substantial healthcare expenditures, and a well-established medical infrastructure. The U.S. is a major player in this region, with significant healthcare spending and the presence of leading defibrillator manufacturers. The U.S. healthcare expenditure was $4.5 trillion in 2022, highlighting the market potential for defibrillator devices.
Key Players
The key players profiled in the defibrillator market report are Medtronic plc (Ireland), Boston Scientific Corporation (U.S.), Abbott Laboratories (U.S.), Biotronik Se & Co., Kg (Germany), LivaNova plc (U.K.), Stryker Corporation (U.S.), Koninklijke Philips N.V. (Netherlands), Nihon Kohden Corporation (Japan), Progetti Srl (Italy), Fukuda Denshi Co., Ltd. (Japan), Schiller AG (Switzerland), and ZOLL Medical Corporation (U.S.).
Buy now ; https://www.meticulousresearch.com/Checkout/76718964
Key questions answered in the report:
- Which are the high-growth market segments in terms of defibrillators by product, age group, end user, and geography?
- What was the historical market for defibrillators across the globe?
- What are the market forecasts and estimates for the period 2024–2031?
- What are the major drivers, restraints, opportunities, and challenges in the defibrillator market?
- Who are the major players operating in the defibrillator market?
- What is the competitive landscape like, and who are the leaders in the defibrillator market?
- What are the recent developments in the defibrillator market?
- What are the different strategies adopted by the major players in the defibrillator market?
- What are the geographical trends and high-growth regions/countries?
Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research